Related Experiment Video
Updated: Sep 21, 2025
10:46
Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
Published on: September 1, 2023
3.4K
Circulating malondialdehyde level in patients with epilepsy: A meta-analysis
Huaiyu Sun1, Jiaai Li1, Buajieerguli Maimaiti1
1Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
Seizure
|May 31, 2022
Summary
Patients with epilepsy (PWE) show significantly higher malondialdehyde (MDA) levels, a marker of oxidative stress, in their blood compared to healthy individuals. This meta-analysis confirms MDA as a potential indicator of oxidative damage in epilepsy.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Research
Background:
- Oxidative stress plays a role in the pathophysiology of epilepsy.
- Malondialdehyde (MDA) is a key biomarker for assessing oxidative damage.
Purpose of the Study:
- To conduct a meta-analysis evaluating circulating malondialdehyde (MDA) levels in patients with epilepsy (PWE) compared to healthy controls.
- To determine if MDA levels differ across various sample types (erythrocytes, serum, plasma) in PWE.
Main Methods:
- A systematic meta-analysis of 15 published studies.
- Inclusion of data from 559 PWE and 853 healthy controls.
- Analysis of MDA levels in erythrocytes, serum, and plasma.
Main Results:
- Significantly elevated MDA levels were observed in PWE across serum, plasma, and red blood cells compared to controls.
- Subgroup analyses by sex, region, and detection method consistently showed higher MDA in PWE.
- MDA levels were notably higher in Asian PWE compared to non-Asian PWE.
Conclusions:
- Circulating MDA levels are significantly increased in PWE, suggesting its role as a potential indicator of oxidative damage in epilepsy.
- This meta-analysis represents the first comprehensive evaluation of circulating MDA levels in PWE.
- Findings highlight the utility of MDA as a biomarker in epilepsy research.
